A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects

NCT01221818 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammatory Bowel Disease

Interventions

DRUG: E6007
DRUG: E6007
DRUG: E6007
DRUG: E6007
DRUG: E6007
DRUG: E6007

Sponsor

Eisai Inc.